Thrombosis and systemic lupus erythematosus: The hopkins lupus cohort perspective

Research output: Contribution to journalArticle

Abstract

Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.

Original languageEnglish (US)
Pages (from-to)191-193
Number of pages3
JournalScandinavian Journal of Rheumatology
Volume25
Issue number4
StatePublished - 1996

Fingerprint

Systemic Lupus Erythematosus
Thrombosis
Atherosclerosis
Hydroxychloroquine
Lupus Coagulation Inhibitor
Antiphospholipid Antibodies
Antiphospholipid Syndrome
Thrombophilia
Homocysteine
Vasculitis
Hyperlipidemias
Antigen-Antibody Complex
Blood Vessels
Cohort Studies
Prospective Studies
Hypertension
Incidence
Wounds and Injuries

Keywords

  • Anticardiolipin
  • Antiphospholipid antibodies
  • Lupus anticoagulant
  • Thrombosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Thrombosis and systemic lupus erythematosus : The hopkins lupus cohort perspective. / Petri, Michelle.

In: Scandinavian Journal of Rheumatology, Vol. 25, No. 4, 1996, p. 191-193.

Research output: Contribution to journalArticle

@article{27038c3b0a2e483fb6d295b998c73247,
title = "Thrombosis and systemic lupus erythematosus: The hopkins lupus cohort perspective",
abstract = "Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.",
keywords = "Anticardiolipin, Antiphospholipid antibodies, Lupus anticoagulant, Thrombosis",
author = "Michelle Petri",
year = "1996",
language = "English (US)",
volume = "25",
pages = "191--193",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Thrombosis and systemic lupus erythematosus

T2 - The hopkins lupus cohort perspective

AU - Petri, Michelle

PY - 1996

Y1 - 1996

N2 - Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.

AB - Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.

KW - Anticardiolipin

KW - Antiphospholipid antibodies

KW - Lupus anticoagulant

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0029764927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029764927&partnerID=8YFLogxK

M3 - Article

C2 - 8792794

AN - SCOPUS:0029764927

VL - 25

SP - 191

EP - 193

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 4

ER -